title: A trial comparing nucleoside monotherapy with sequential therapy with 3 drugs in HIV-infected patients.
abstract: 53 HIV-positive patients, 66% of them zidovudine-experienced, were randomized to receive monotherapy with zidovudine or sequential therapy with zidovudine, didanosine and zalcitabine. Clinical end points, CD4 cell count change, and analysis abnormalities showed better results with sequential therapy.
authors.affiliation: Medicine Department, Hospital General, Castellón, Spain.
authors.forename: B
authors.initials: B
authors.lastname: Roca
authors.forename: P
authors.initials: P
authors.lastname: Olmos
authors.forename: C
authors.initials: C
authors.lastname: Mínguez
authors.forename: A
authors.initials: A
authors.lastname: Arnedo
authors.forename: J
authors.initials: J
authors.lastname: Usó
authors.forename: C
authors.initials: C
authors.lastname: Teruel
authors.forename: M
authors.initials: M
authors.lastname: Segarra
authors.forename: A
authors.initials: A
authors.lastname: Sáez-Royuela
authors.forename: E
authors.initials: E
authors.lastname: Simón
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D016049:Didanosine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome; D016047:Zalcitabine / Q000627:therapeutic use*; D015215:Zidovudine / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D016047:Zalcitabine; D016049:Didanosine